According to the NCI website, ARV-110 is an orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity.  Check for active clinical trials using this agent. (NCI Thesaurus)

Link to National Cancer Institute